"Recombinant Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins prepared by recombinant DNA technology.
| Descriptor ID |
D011994
|
| MeSH Number(s) |
D12.776.828
|
| Concept/Terms |
Recombinant Proteins- Recombinant Proteins
- Proteins, Recombinant
- Proteins, Biosynthetic
- Biosynthetic Proteins
Proteins, Recombinant DNA- Proteins, Recombinant DNA
- DNA Proteins, Recombinant
- Recombinant DNA Proteins
- DNA Recombinant Proteins
- Proteins, DNA Recombinant
- Recombinant Proteins, DNA
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Proteins".
This graph shows the total number of publications written about "Recombinant Proteins" by people in this website by year, and whether "Recombinant Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 5 | 5 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 11 | 11 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 8 | 8 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 6 | 6 |
| 2003 | 1 | 13 | 14 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 10 | 10 |
| 2008 | 0 | 22 | 22 |
| 2009 | 0 | 11 | 11 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 5 | 5 |
| 2012 | 0 | 15 | 15 |
| 2013 | 0 | 7 | 7 |
| 2014 | 0 | 9 | 9 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 5 | 6 |
| 2017 | 2 | 5 | 7 |
| 2019 | 0 | 4 | 4 |
| 2020 | 1 | 3 | 4 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Proteins" by people in Profiles.
-
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
-
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
-
Evaluation of artificial signal peptides for secretion of two lysosomal enzymes in CHO cells. Biochem J. 2021 06 25; 478(12):2309-2319.
-
IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12R?1 internalization and suppress EAE. Proc Natl Acad Sci U S A. 2020 09 01; 117(35):21557-21567.
-
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. Pediatr Neurol. 2020 09; 110:64-70.
-
Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biol. 2020 02; 10(2):190235.
-
Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
-
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. J Acquir Immune Defic Syndr. 2019 12 15; 82(5):503-513.
-
In-Vivo Efficacy of Recombinant Human Hyaluronidase (rHuPH20) Injection for Accelerated Healing of Murine Retrocalcaneal Bursitis and Tendinopathy. J Orthop Res. 2020 01; 38(1):59-69.
-
Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.